BIAF bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United Sta…
Industry Peers
Diagnostics & Research| Headline | Source | Time |
|---|---|---|
Older | ||
 bioAffinity Technologies Builds Momentum for Non-Invasive Lung Cancer Detection bioAffinity Technologies (NASDAQ:BIAF) is continuing to build momentum behind its non-invasive lung cancer diagnostic, CyPath Lung, with new clinical evidence and an expanding route into the US federal healthcare market. The company is presenting real-world clinical cases and new research focused on veteran and military populations at the 2026 NAVREF Annual Conference, highlighting the potential role of CyPath Lung in helping physicians make more informed diagnostic decisions. | ||
 bioAffinity Technologies to Showcase Lung Cancer Test Data at Veterans’ Research Conference bioAffinity Technologies (NASDAQ:BIAF) will present new clinical findings on its noninvasive lung cancer test, CyPath® Lung, at the 2026 NAVREF Annual Conference, running September 27–30 in Arlington, Virginia. The company is set to unveil two posters focused on the test’s use in veteran and military healthcare settings. | ||
 bioAffinity Technologies Secures Hong Kong Patent for CyPath Lung Cancer Diagnostic The new patent extends intellectual property protection for the company’s noninvasive lung cancer detection technology in Asia, complementing its existing Chinese patent. Key Investor TakeawaysbioAffinity Technologies (NASDAQ:BIAF) has received a Hong Kong patent covering core technology used in its CyPath Lung diagnostic test. | ||
 bioAffinity’s AI Lung-Cancer Stock Jumped Nearly 48% After a Reverse Split. What Would Have to Go Right? bioAffinity Technologies jumped 47.95% on September 2, one day after announcing that it was advancing the potential use of CyPath Lung for post-treatment surveillance of lung-cancer patients. The move followed a 1-for-15 reverse split that became effective for trading on August 24, a combination that can produce dramatic percentage swings in a thinly traded stock. […] | ||
 bioAffinity Technologies Shares Rise After CyPath Lung Surveillance Update bioAffinity Technologies (NASDAQ:BIAF) shares rose 39. 4% in premarket trading after the company announced that its CyPath® Lung noninvasive diagnostic test is now positioned for post-curative surveillance of lung cancer recurrence. | ||
 bioAffinity Technologies Advances CyPath Lung for Post-Treatment Lung Cancer Surveillance The company is evaluating an additional application for CyPath Lung that could complement CT imaging when monitoring lung cancer survivors for recurrence or new primary cancers. Key Investor TakeawaysbioAffinity Technologies (NASDAQ:BIAF) is advancing CyPath Lung for potential use in post-treatment lung cancer surveillance, expanding its focus beyond early detection. | ||
 bioAffinity Technologies Signs Nationwide Federal Healthcare Distribution Agreement for CyPath Lung bioAffinity Technologies, Inc. (NASDAQ:BIAF) has signed a nationwide federal healthcare distribution agreement with AvMEDICAL for CyPath Lung, giving the lung cancer diagnostic access to an established government sales and procurement network. | ||
 BIAF vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now? bioAffinity and Biodesix pursue different cancer diagnostics strategies, but which oncology stock offers better long-term upside? Let's dive in. | ||